Inclusion Criteria

- Diagnosis of one of the following hematological malignancies:

- CML, with 1 of the following:

- In first CP AND failed imatinib mesylate therapy, defined as failure to
obtain a hematologic remission at 3 months or a major cytogenetic response
(i.e., Ph+ cells < 35%) at 6 months or demonstrated clonal evolution or
disease progression during therapy

- In accelerated phase with < 15% blasts

- In blast crisis that has entered into a second CP following induction
chemotherapy

- AML, with 1 of the following:

- In second or subsequent complete remission (CR) (i.e., < 5% blasts by
morphology, no residual leukemia by flow cytometry, and absence of
cytogenetic abnormalities)

- Failed primary induction chemotherapy, but subsequently entered into a CR
with ≤ 2 subsequent re-induction chemotherapy treatment(s)

- In first CR with intermediate-risk or poor-risk cytogenetics

- ALL with 1 of the following:

- In second or subsequent CR

- In first CR AND presence of t(9;22)

- MDS, with the following:

- High-risk disease, defined by IPSS score of ≥ 1.5 at diagnosis AND meets 1
of the following criteria:

- ≤ 10% blasts at diagnosis

- In morphologic CR (< 5% blasts) following cytoreductive chemotherapy

- CMML, with 1 of the following:

- ≤ 10% blasts at diagnosis

- In morphologic CR (< 5% blasts) following cytoreductive chemotherapy

- CLL/PLL with the following:

- Rai stage I-IV disease

- Failed ≥ 1 prior chemotherapy regimen (including fludarabine phosphate) or
ASCT

- Documented chemosensitive or stable, non-bulky disease prior to transplant,
defined as < 20% bone marrow involvement AND lymph node size < 3 cm in
axial diameter

- No bulky tumor masses, elevated lactate dehydrogenase (LDH), B symptoms, or
progressive disease prior to transplant

- Low-grade non-Hodgkin lymphoma (NHL) (i.e., small lymphocytic lymphoma,
follicular center lymphoma [grade 1 or 2], marginal zone lymphoma, or B-cell
lymphoma), with the following criteria:

- Failed ≥ 1 prior chemotherapy regimen or ASCT

- Documented chemosensitive or stable, non-bulky disease prior to transplant,
defined as < 20% bone marrow involvement AND lymph node size < 3 cm in
axial diameter

- Received ≤ 3 prior chemotherapy regimens (monoclonal antibody therapy and
involved-field radiotherapy are not considered a prior regimen)

- No bulky tumor masses, elevated LDH, B symptoms, or progressive disease
prior to transplant

- Mantle cell lymphoma, with the following:

- Failed to achieve remission or recurred after either conventional
chemotherapy or ASCT

- Responsive or stable disease to most recent prior therapy

- No bulky tumor masses, elevated LDH, B symptoms, or progressive disease
prior to transplant

- Intermediate-grade NHL (i.e., follicular center lymphoma [grade 3] or diffuse
large cell lymphoma), meeting the following criteria:

- Failed to achieve remission or recurred after either conventional
chemotherapy or ASCT

- Documented chemosensitive, non-bulky disease prior to transplant, defined
as at least a partial remission to salvage chemotherapy (≥ 50% reduction in
diameter of all disease sites)

- No bulky tumor masses, elevated LDH, B symptoms, or progressive disease
prior to transplant

- Hodgkin lymphoma, with the following:

- Relapsed after prior ASCT OR after ≥ 2 combination chemotherapy regimens
and ineligible for ASCT

- Documented chemosensitive, non-bulky disease prior to transplant, defined
as at least a partial remission to salvage chemotherapy (≥ 50% reduction in
diameter of all disease sites)

- No bulky tumor masses, elevated LDH, B symptoms, or progressive disease
prior to transplant

- Peripheral T-cell NHL, with the following:

- Failed to achieve remission or recurred after either conventional
chemotherapy or ASCT

- Documented chemosensitive, non-bulky disease prior to transplant, defined
as at least a partial remission to salvage chemotherapy (≥ 50% reduction in
diameter of all disease sites)

- No bulky tumor masses, elevated LDH, B symptoms, or progressive disease
prior to transplant

- Myeloproliferative syndrome with poor risk features, meeting 1 of the following
criteria:

- < 55 years old AND Lille score of 1

- Lille score of 2

- HgB < 10 g/dL AND abnormal karyotype

- High-risk disease, with 1 of the following:

- Age 40-72 years

- Any age AND deemed to be at significantly increased risk of morbidity and death
following a standard, myeloablative unrelated donor stem cell transplant (e.g.,
received extensive prior therapy, including ASCT)

- HLA-matched unrelated donor available, with 1 of the following:

- 8/8 match at HLA-A, B, C, or DR loci by high-resolution genotyping

- Single allelic mismatch at either the HLA-B or HLA-C loci donor by
high-resolution molecular typing

- No single allelic mismatch at HLA-A or HLA-DR loci

- KPS 80-100%

- Adapted weighted Charlson Comorbidity Index < 3

- Serum creatinine ≤ 2.0 mg/dL

- AST or ALT < 3 times upper limit of normal (ULN)

- Total bilirubin < 1.5 times ULN

- LVEF ≥ 45%

- DLCO > 50%

- No hypoxia at rest with oxygen saturation < 92% on room air (corrected with
bronchodilator therapy)

- No other severe pulmonary function abnormalities

- No HIV infection

- No active hepatitis B or C infection that, in the opinion of a gastroenterologist or
the transplant committee, places the patient at moderate to high risk for developing
severe hepatic disease

- No active opportunistic infection (e.g., fungal pneumonia, tuberculosis, or viral
infection)